Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer

NCT02689284 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

95

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric Cancer
Stomach Cancer
Esophageal Cancer

Interventions

BIOLOGICAL: Margetuximab 10 mg/kg
BIOLOGICAL: Margetuximab 15 mg
BIOLOGICAL: Pembrolizumab

Sponsor

MacroGenics

Collaborators

[object Object]